DURECT Corp
NASDAQ:DRRX

Watchlist Manager
DURECT Corp Logo
DURECT Corp
NASDAQ:DRRX
Watchlist
Price: 1.91 USD -1.04% Market Closed
Market Cap: 59.3m USD

Operating Margin
DURECT Corp

-536.3%
Current
-436%
Average
5.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-536.3%
=
Operating Profit
-16.7m
/
Revenue
3.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
DURECT Corp
NASDAQ:DRRX
59.3m USD
-536%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
491.8B USD
27%
CH
Roche Holding AG
SIX:ROG
271.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP
24%
US
Merck & Co Inc
NYSE:MRK
274.9B USD
38%
CH
Novartis AG
SIX:NOVN
218.8B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
144.9B USD
29%
No Stocks Found

DURECT Corp
Glance View

Market Cap
59.3m USD
Industry
Pharmaceuticals

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.

DRRX Intrinsic Value
12.08 USD
Undervaluation 84%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-536.3%
=
Operating Profit
-16.7m
/
Revenue
3.1m
What is the Operating Margin of DURECT Corp?

Based on DURECT Corp's most recent financial statements, the company has Operating Margin of -536.3%.

Back to Top